Tecartus demonstrates high response rate in adults with relapsed or refractory B-cell acute lymphoblastic leukemia – Kite/Gilead
Kite, a Gilead Company announced results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, open-label Phase 1/II study evaluating its chimeric antigen receptor (CAR) T-cell therapy… read more.
